Sector News

AZ could jump into the Medivation fray with $10B bid: Report

July 12, 2016
Life sciences

While several drugmakers may be circling coveted buyout target Medivation, so far, Sanofi is the only one that’s come through with a bid. But that could all be changing soon.

AstraZeneca is considering putting forth its own offer of £7.7 billion ($10 billion), The Sunday Times reports. According to the British newspaper, AZ scoped out Medivation earlier in the year, and it’s still interested in potentially making a move.

It’s easy to see why AZ–and plenty of its peers–may want to snap up the San Francisco drugmaker. Medivation has something special in Xtandi, a prostate cancer pill that’s already on the market–and racking up blockbuster sales. Plus, it’s got a shiny pipeline prospect in talazoparib, a candidate CEO David Hung has touted as a “best-in-class” PARP inhibitor.

AstraZeneca, which is working to notch a turnaround, could certainly use the cancer revenues; it’s marked oncology as a key field that’ll help dig it out of its slump and hit the hefty sales projections it put up when it was trying to evade hostile suitor Pfizer back in 2014. It also already boasts a prostate cancer-fighter–Zoladex–and it’s investigating PARP med Lynparza in that area, too, so there’s a “significant fit” for Xtandi in its portfolio, Credit Suisse analysts wrote recently.

But plenty of AZ’s rivals think they’ve got their own fit with Medivation, with eager Sanofi among them. The French pharma giant dropped a hostile play last week after Medivation included it in a set of potential bidders it invited to the table, inking confidentiality agreements with “a number of parties.” Pfizer, Amgen, Gilead, Celgene and others have reportedly been eying a deal, too.

And as The Telegraph pointed out in April, AZ and CEO Pascal Soriot have been known to avoid bidding wars; getting into one now could especially spook shareholders, considering an earlier promise from Soriot to largely avoid big buyouts.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

July 14, 2024

Flagship raises $3.6B for biotech investing

Life sciences

Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised since 2021 to $6.4 billion. Meanwhile, Flagship announced more than a dozen promotions and new hires in its leadership ranks. The changes include the promotions of Lovisa Afzelius and Paul Biondi to general partner and the addition of Dina Ciarimboli as general counsel and executive partner.

July 14, 2024

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

Life sciences

After 15 years at Pfizer, including a career-defining pandemic period, the chief scientific officer will leave the Big Pharma once the drugmaker finds his successor. Dolsten joined Pfizer when the company closed a megamerger with Wyeth in 2009. Pfizer made Dolsten president of worldwide R&D the following year. The executive has stayed at the top of Pfizer’s R&D tree ever since.

July 14, 2024

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Life sciences

Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 contract development and manufacturing organizations (CDMOs) in the world, Lotte said in a press release.

How can we help you?

We're easy to reach